The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. - Wikidata - wikimedia - TriplyDB

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

http://www.wikidata.org/entity/Q43934617

about

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial Statins for multiple sclerosis Statins for multiple sclerosis Statins for multiple sclerosis Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells Pleiotropic effects of statins The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?Put your heart into the joint benefits of statins!TCR Signal Strength Alters T-DC Activation and Interaction Times and Directs the Outcome of Differentiation Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis T cell metabolism drives immunity Cell Fusion along the Anterior-Posterior Neuroaxis in Mice with Experimental Autoimmune Encephalomyelitis Current and Emerging Uses of Statins in Clinical Therapeutics: A Review Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism Microbial isoprenoid biosynthesis and human gammadelta T cell activation Ongoing clinical trials of the pleiotropic effects of statins Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy Statin therapy and autoimmune disease: from protein prenylation to immunomodulation Astrocytes in multiple sclerosis: a product of their environment The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial)Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells.p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases.New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics A large Rab GTPase encoded by CRACR2A is a component of subsynaptic vesicles that transmit T cell activation signals.Statin treatment in multiple sclerosis: a systematic review and meta-analysis.Emerging therapies in multiple sclerosis.Importance of microbial natural products and the need to revitalize their discovery.The effects of atorvastatin in experimental autoimmune uveitis TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis.Transient decrease in circulating dendritic cell precursors after acute stroke: potential recruitment into the brain.Effect of HMG-CoA reductase inhibitors on activation of human gammadeltaT cells induced by Mycobacterium tuberculosis antigens.

P2860

Q21144329-EEC10C06-06B5-467F-9244-514BDB67EDA1 Q21559486-237CC237-68A2-40D2-887E-8F5B5DE8718D Q24234119-80FFB79E-20CA-448B-816D-350AB6BA6117 Q24235592-25AB7CEA-A25E-4519-BCB4-F384A646EDA9 Q24240191-7A73F747-E3AD-442A-8630-3AA6141C4010 Q24289002-6BEBC231-813F-458A-87A2-F1FBEF83EFC2 Q24647863-44E94232-9D7E-470B-8630-9260101AB82C Q24684244-B04F68C7-1519-4173-B94E-5D02C4CBA93B Q24796000-8117BC4B-523D-48A6-9EA3-F4F3C06ACCC3 Q24802262-95311538-4E23-468D-9BFB-6E9A6564398E Q24804153-3EC02F66-CB12-4DA6-811E-F982032D8211 Q24805105-92B2F5DA-8AA0-465D-A131-B8D93CF631C2 Q26772704-6AE907F1-5173-4C96-933B-E6650F6A2D69 Q26780531-EEF79EAA-6145-4AC8-8704-962A3E631FA7 Q26799575-8E663759-45FA-4E79-A476-DB0735149325 Q27301922-71256A3C-52ED-47AD-A899-B739719FBF11 Q28076346-C7BEA865-0872-4D62-9B06-74E368A59D0D Q28083961-D513F70E-5CCA-4625-B9E6-6643B70E6F8E Q28208141-5D5CD043-E240-41CE-AADA-826CA84BAA0A Q28219321-FA18A94D-743C-4734-9460-B0CB8C04642C Q28235507-B5B9D616-81C7-4C5A-99D1-AD3E6875761E Q28236647-C8A57530-C9A2-4FF5-966E-50378912C304 Q28282324-31135575-AD00-440B-BBFD-8645BDB8DF6A Q28299076-DD33E85C-62A0-4775-94F6-BAB37675E8DC Q28388335-D8DD6629-77B9-4C38-8503-1C2DD495189A Q28506096-864ED6EE-64D3-491C-96B4-98EE38AE7537 Q28581447-0CF975E3-324E-4CD4-A113-D3C53D64247E Q28731029-D2598CAE-D06A-44B3-A489-19E71CD6B61E Q28742007-229E214C-99E5-4CFA-92CE-C94CCD692059 Q29568315-5DE0549B-D5CE-4D63-BECC-54AC070929B8 Q30311148-23321F49-ED06-4DA0-B192-089A4240402F Q30371980-D827F796-09BF-4A71-A293-4814E0397A8F Q30808685-668313C2-85F9-4985-B45C-2DD3FA456BCD Q30913423-1639CC1C-F555-4746-B7C1-8D83E46B39FB Q31015100-A828B9E2-9EBB-48BF-90B1-B108CA428280 Q31128037-BE2852D5-E25A-498A-842F-B3CE9233E639 Q33212135-FBED8583-ED8D-41ED-A026-41C1E1B1B15D Q33281667-4F3A3635-A2E1-4140-BBFE-F4817EF9C915 Q33464564-9E976CDC-BD72-4DED-AAF0-D77E5EDFD06D Q33474499-240FE97C-FBC8-4F19-B42F-22F4F1D598CD

P2860

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

http://www.wikidata.org/entity/Q43934617

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

The HMG-CoA reductase inhibito ...... ous system autoimmune disease.

@en

The HMG-CoA reductase inhibito ...... ous system autoimmune disease.

@nl

type

label

The HMG-CoA reductase inhibito ...... ous system autoimmune disease.

@en

The HMG-CoA reductase inhibito ...... ous system autoimmune disease.

@nl

prefLabel

The HMG-CoA reductase inhibito ...... ous system autoimmune disease.

@en

The HMG-CoA reductase inhibito ...... ous system autoimmune disease.

@nl

P1433

Q43934617-995849D3-E73D-4184-BE5A-735E7A246C3F

P1476

Q43934617-6F70F867-80B4-41C3-ACAD-5426648C1648

P2093

Q43934617-0E396191-7BF4-4A31-8F8D-B3EAD4EC8FD2

Q43934617-84F20289-4F2E-499B-8FB7-95D13580218A

Q43934617-9F84F835-9B9B-4ECE-8E57-5DF59CC336DA

Q43934617-A284F606-71AC-42C0-B954-61C8D9509C04

Q43934617-A56D149C-F7A2-427B-9D12-ECC2B2E70AE5

Q43934617-B373A0EC-0063-4218-B0D8-E4600B2EB6DB

Q43934617-C604EBB4-06DD-400A-B233-076D29CF8D3E

Q43934617-E8BA3AD7-ABDD-4C71-93AC-9EB7B00A9BB4

Q43934617-EE36A8DE-FD6C-4B67-A435-564CBE6261BE

Q43934617-FE5503F6-75E6-4CCE-A2B5-CC27A194CD07

P2888

Q43934617-CE823D4F-6E7D-41BD-AADF-BDB747E0EA90

P304

Q43934617-58D92F8C-516A-4862-AE6A-DE7A823EC23B

P31

Q43934617-9FA28591-23A7-4FA3-9CF4-2B4784CBEFF3

P356

Q43934617-DB2255BF-2213-44D5-82E5-3E4AB1A46661

P407

Q43934617-B87E3166-6B03-4297-9A91-17D6C88091CE

P433

Q43934617-896F7FFE-9DB8-4807-8579-25A19D39D737

P478

Q43934617-33A29BB5-2BC5-4B99-A82E-ADAFCC343566

P50

Q43934617-7283F398-D70A-4953-B05C-4B6CD8AD41AF

P577

Q43934617-E80350EE-DD1C-4C8F-8930-A41FBA1C2264

P5875

Q43934617-EABE90EE-9ED1-47CA-98AC-06ED46DF4A8F

P6179

Q43934617-D27124D1-472E-4DA0-88EC-A74B65CBD3EF

P698

Q43934617-886FD676-2472-4763-AE6C-31E0B1390E85

P921

Q43934617-A47C77AD-7572-4EA7-9E33-AD34ACB5C6B0

P356

P1433

P1476

The HMG-CoA reductase inhibito ...... ous system autoimmune disease.

@en

P2093

Dennis J Mitchell

http://www.w3.org/2001/XMLSchema#string

Eun Mi Hur

http://www.w3.org/2001/XMLSchema#string

Jennifer L Radosevich

http://www.w3.org/2001/XMLSchema#string

Juan C Patarroyo

http://www.w3.org/2001/XMLSchema#string

Lawrence Steinman

http://www.w3.org/2001/XMLSchema#string

Manuel Bravo

http://www.w3.org/2001/XMLSchema#string

Pedro J Ruiz

http://www.w3.org/2001/XMLSchema#string

Raymond A Sobel

http://www.w3.org/2001/XMLSchema#string

Sawsan Youssef

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

P2888

P304

78-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE01158

http://www.w3.org/2001/XMLSchema#string

P407

P433

6911

http://www.w3.org/2001/XMLSchema#string

P478

420

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11044488

http://www.w3.org/2001/XMLSchema#string

P6179

1001566151

http://www.w3.org/2001/XMLSchema#string

P698

12422218

http://www.w3.org/2001/XMLSchema#string

P921